Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Larkin, J; Del Vecchio, M; Mandala, M; Gogas, H; Fernandez, AMA; Dalle, S; Cowey, CL; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Marquez-Rodas, I; Butler, MO; Giacomo, AMD; Middleton, MR; Lutzky, J; Cruz-Merino, LD; Arenberger, P; Atkinson, V; Hill, AG; Fecher, LA; Millward, M; Nathan, PD; Khushalani, NI; Queirolo, P; Ritchings, C; Lobo, M; Askelson, M; Tang, H; Dolfi, S; Ascierto, PA; Weber, J

Larkin, J (通讯作者)，Royal Marsden NHS Fdn Trust, London, England.;Larkin, J (通讯作者)，Royal Marsden NHS Fdn Trust, 203 Fulham Rd, London SW3 6JJ, England.

CLINICAL CANCER RESEARCH, 2023; 29 (17): 3352

Abstract

Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free su......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索